US5436146A
(en)
*
|
1989-09-07 |
1995-07-25 |
The Trustees Of Princeton University |
Helper-free stocks of recombinant adeno-associated virus vectors
|
PT733103E
(pt)
*
|
1993-11-09 |
2004-07-30 |
Targeted Genetics Corp |
Criacao de elevados titulos de vectores de aav recombinantes
|
JPH10501686A
(ja)
|
1994-04-13 |
1998-02-17 |
ザ ロックフェラー ユニヴァーシティ |
神経系の細胞へのdnaのaav仲介送達
|
US5658785A
(en)
*
|
1994-06-06 |
1997-08-19 |
Children's Hospital, Inc. |
Adeno-associated virus materials and methods
|
US20020159979A1
(en)
|
1994-06-06 |
2002-10-31 |
Children's Hospital, Inc. |
Adeno-associated virus materials and methods
|
WO1996012010A1
(de)
*
|
1994-10-13 |
1996-04-25 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Bereitstellung von rep-negativen aav-mutanten und hierfür verwendbare zellen
|
US5856152A
(en)
*
|
1994-10-28 |
1999-01-05 |
The Trustees Of The University Of Pennsylvania |
Hybrid adenovirus-AAV vector and methods of use therefor
|
US6342390B1
(en)
|
1994-11-23 |
2002-01-29 |
The United States Of America As Represented By The Secretary Of Health And Human Services |
Lipid vesicles containing adeno-associated virus rep protein for transgene integration and gene therapy
|
US6326356B1
(en)
|
1996-10-18 |
2001-12-04 |
Board Of Regents, The University Of Texas System |
Suppression of neu overexpression using a mini-E1A gene
|
WO1996017947A1
(en)
*
|
1994-12-06 |
1996-06-13 |
Targeted Genetics Corporation |
Packaging cell lines for generation of high titers of recombinant aav vectors
|
US6924128B2
(en)
|
1994-12-06 |
2005-08-02 |
Targeted Genetics Corporation |
Packaging cell lines for generation of high titers of recombinant AAV vectors
|
US5843742A
(en)
*
|
1994-12-16 |
1998-12-01 |
Avigen Incorporated |
Adeno-associated derived vector systems for gene delivery and integration into target cells
|
US6752987B1
(en)
|
1995-02-28 |
2004-06-22 |
The Regents Of The University Of California |
Adenovirus encoding human adenylylcyclase (AC) VI
|
EP0760682A4
(en)
|
1995-02-28 |
1998-09-09 |
Univ California |
ANGIOGENIC THERAPY BY GENE TRANSFER
|
US5756283A
(en)
*
|
1995-06-05 |
1998-05-26 |
The Trustees Of The University Of Pennsylvania |
Method for improved production of recombinant adeno-associated viruses for gene therapy
|
US6281010B1
(en)
|
1995-06-05 |
2001-08-28 |
The Trustees Of The University Of Pennsylvania |
Adenovirus gene therapy vehicle and cell line
|
US6093570A
(en)
*
|
1995-06-07 |
2000-07-25 |
The University Of North Carolina At Chapel Hill |
Helper virus-free AAV production
|
US5622856A
(en)
*
|
1995-08-03 |
1997-04-22 |
Avigen |
High efficiency helper system for AAV vector production
|
EP0842287B1
(en)
*
|
1995-08-03 |
2004-02-04 |
Avigen, Inc. |
High efficiency helper system for aav vector production
|
US6001650A
(en)
|
1995-08-03 |
1999-12-14 |
Avigen, Inc. |
High-efficiency wild-type-free AAV helper functions
|
US6162796A
(en)
*
|
1995-09-27 |
2000-12-19 |
The Rockefeller University |
Method for transferring genes to the heart using AAV vectors
|
US6086913A
(en)
*
|
1995-11-01 |
2000-07-11 |
University Of British Columbia |
Liposomal delivery of AAV vectors
|
US6004797A
(en)
*
|
1995-11-09 |
1999-12-21 |
Avigen, Inc. |
Adenovirus helper-free recombinant AAV Virion production
|
US20060088938A1
(en)
*
|
1995-12-15 |
2006-04-27 |
Mitchell Lloyd G |
Methods and compositions for use in spliceosome mediated RNA trans-splicing in plants
|
US20020193580A1
(en)
*
|
1995-12-15 |
2002-12-19 |
Mitchell Lloyd G. |
Methods and compositions for use in spliceosome mediated RNA trans-splicing
|
US20030027250A1
(en)
*
|
1995-12-15 |
2003-02-06 |
Mitchell Lloyd G. |
Methods and compositions for use in spliceosome mediated RNA trans-splicing
|
US5952221A
(en)
*
|
1996-03-06 |
1999-09-14 |
Avigen, Inc. |
Adeno-associated virus vectors comprising a first and second nucleic acid sequence
|
DE19608751B4
(de)
|
1996-03-06 |
2006-05-18 |
Medigene Ag |
Verwendung eines Adeno-assoziierten Virus-Vektors zur Steigerung der Immunogenität von Zellen
|
US6294370B1
(en)
|
1997-06-24 |
2001-09-25 |
Medigene Ag |
System for the production of AAV vectors
|
US6541012B2
(en)
|
1996-06-24 |
2003-04-01 |
Christoph Bogedain |
System for the production of AAV vectors
|
DE19625188A1
(de)
*
|
1996-06-24 |
1998-01-08 |
Medigene Gmbh |
System zur Herstellung von AAV-Vektoren
|
IL128736A0
(en)
|
1996-09-06 |
2000-01-31 |
Univ Pennsylvania |
Methods using cre-lox for production of recombinant adeno-associated viruses
|
US5866552A
(en)
*
|
1996-09-06 |
1999-02-02 |
The Trustees Of The University Of Pennsylvania |
Method for expressing a gene in the absence of an immune response
|
EP0931158A1
(en)
*
|
1996-09-06 |
1999-07-28 |
The Trustees Of The University Of Pennsylvania |
An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
|
WO1998022608A2
(en)
*
|
1996-11-18 |
1998-05-28 |
Mcgill University |
Post-mitotic neurons containing adenovirus vectors that modulate apoptosis and growth
|
WO1998027204A2
(en)
*
|
1996-12-18 |
1998-06-25 |
Targeted Genetics Corporation |
Aav split-packaging genes and cell lines comprising such genes for use in the production of recombinant aav vectors
|
WO1998046728A1
(en)
*
|
1997-04-14 |
1998-10-22 |
Cell Genesys, Inc. |
Methods for increasing the efficiency of recombinant aav product
|
US6251677B1
(en)
|
1997-08-25 |
2001-06-26 |
The Trustees Of The University Of Pennsylvania |
Hybrid adenovirus-AAV virus and methods of use thereof
|
US6566118B1
(en)
|
1997-09-05 |
2003-05-20 |
Targeted Genetics Corporation |
Methods for generating high titer helper-free preparations of released recombinant AAV vectors
|
PT1944362E
(pt)
|
1997-09-05 |
2016-01-27 |
Genzyme Corp |
Métodos de produção de preparações de alto título de vetores aav recombinantes desprovidos de adjuvantes
|
US6989264B2
(en)
*
|
1997-09-05 |
2006-01-24 |
Targeted Genetics Corporation |
Methods for generating high titer helper-free preparations of released recombinant AAV vectors
|
US6346415B1
(en)
*
|
1997-10-21 |
2002-02-12 |
Targeted Genetics Corporation |
Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors
|
US6642051B1
(en)
*
|
1997-10-21 |
2003-11-04 |
Targeted Genetics Corporation |
Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors
|
IT1297074B1
(it)
*
|
1997-11-21 |
1999-08-03 |
Angeletti P Ist Richerche Bio |
Forme ormone-dipendenti delle proteine rep del virus adeno-associato (aav-2), sequenze di dna codificanti per esse, vettori che le
|
US6953690B1
(en)
|
1998-03-20 |
2005-10-11 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for helper-free production of recombinant adeno-associated viruses
|
EP2942393A1
(en)
|
1998-09-04 |
2015-11-11 |
Genzyme Corporation |
Methods for generating high titer helper-free preparations of released recombinant aav vectors
|
EP1939215A1
(en)
|
1998-10-22 |
2008-07-02 |
The University of Montana |
Omp85 proteins of neisseria gonorrhoeae and neisseria meningitidis, compositions containing same and methods of use thereof
|
US6303362B1
(en)
*
|
1998-11-19 |
2001-10-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Adenoviral vector and methods for making and using the same
|
US6387368B1
(en)
|
1999-02-08 |
2002-05-14 |
The Trustees Of The University Of Pennsylvania |
Hybrid adenovirus-AAV virus and methods of use thereof
|
US6893865B1
(en)
|
1999-04-28 |
2005-05-17 |
Targeted Genetics Corporation |
Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles
|
US6793926B1
(en)
|
1999-05-27 |
2004-09-21 |
Genovo, Inc. |
Methods for production of a recombinant adeno-associated virus
|
JP2003501043A
(ja)
*
|
1999-05-28 |
2003-01-14 |
ターゲティッド ジェネティクス コーポレイション |
腫瘍壊死因子(tnf)関連障害において、tnfのレベルを低下させるための方法および組成物
|
EP1939300A1
(en)
|
1999-05-28 |
2008-07-02 |
Targeted Genetics Corporation |
Methods and compositions for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
|
EP1916258B1
(en)
|
1999-08-09 |
2014-04-23 |
Targeted Genetics Corporation |
Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs
|
EP1204739B1
(en)
|
1999-08-09 |
2008-08-06 |
Targeted Genetics Corporation |
Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs
|
US7115391B1
(en)
|
1999-10-01 |
2006-10-03 |
Genovo, Inc. |
Production of recombinant AAV using adenovirus comprising AAV rep/cap genes
|
WO2001025253A2
(en)
|
1999-10-01 |
2001-04-12 |
The University Of North Carolina At Chapel Hill |
Temperature-sensitive regulation of viral vector production
|
JP2003511082A
(ja)
*
|
1999-10-12 |
2003-03-25 |
ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル |
第viii因子をコードするアデノ随伴ウィルスベクターとその使用法
|
WO2001048164A2
(en)
|
1999-12-27 |
2001-07-05 |
The Regents Of The University Of California |
Modified adenylylcyclase type vi useful in gene therapy for congestive heart failure
|
US6916635B2
(en)
*
|
2000-10-02 |
2005-07-12 |
The Research Foundation Of State University Of New York |
Hybrid adenovirus/adeno-associated virus vectors and methods of use thereof
|
US20040126774A1
(en)
*
|
2001-01-08 |
2004-07-01 |
Mitchell Lioyd G. |
Correction of factor VIII genetic defects using spliceosome mediated RNA trans splicing
|
US6844192B2
(en)
|
2001-06-29 |
2005-01-18 |
Wake Forest University |
Adenovirus E4 protein variants for virus production
|
US6838285B2
(en)
|
2001-09-18 |
2005-01-04 |
Becton Dickinson |
Site specific recombinase based method for producing adenoviral vectors
|
US7399753B2
(en)
*
|
2002-02-25 |
2008-07-15 |
Virxsys Corporation |
Trans-splicing mediated photodynamic therapy
|
EP2277522B1
(en)
*
|
2002-03-01 |
2012-11-21 |
UCB Manufacturing, Inc. |
Methods for increasing or decreasing bone density and identifying molecules
|
US7094399B2
(en)
*
|
2002-05-08 |
2006-08-22 |
Intronn, Inc. |
Use of spliceosome mediated RNA trans-splicing to confer cell selective replication to adenoviruses
|
JP4654033B2
(ja)
*
|
2002-10-23 |
2011-03-16 |
バークシス コーポレーション |
効率的なプレ−トランス−スプライシング分子の同定のためのスクリーニング方法
|
US20040248262A1
(en)
|
2003-01-22 |
2004-12-09 |
Koeberl Dwight D. |
Constructs for expressing lysomal polypeptides
|
WO2004075861A2
(en)
*
|
2003-02-26 |
2004-09-10 |
Children's Hospital, Inc. |
Recombinant adeno-associated virus production
|
WO2005070948A1
(en)
*
|
2004-01-23 |
2005-08-04 |
Intronn, Inc. |
Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated rna trans splicing
|
US7968334B2
(en)
*
|
2004-01-23 |
2011-06-28 |
Virxsys Corporation |
Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing
|
EP1716165A4
(en)
*
|
2004-01-23 |
2008-06-18 |
Virxsys Corp |
EXPRESSION OF APOLIPROTEIN A1 (APOA-1) AND VARIANTS USING SPLICE COMPLEX-INDUCED RNA TRANSPLANT
|
JP2007521835A
(ja)
|
2004-02-10 |
2007-08-09 |
トラスティーズ・オブ・ダートマウス・カレッジ |
ニコチンアミドリボシドキナーゼ組成物およびそれらの使用方法
|
US20060094110A1
(en)
*
|
2004-07-30 |
2006-05-04 |
Mcgarrity Gerard J |
Use of spliceosome mediated RNA trans-splicing for immunotherapy
|
US20060134658A1
(en)
*
|
2004-08-09 |
2006-06-22 |
Garcia-Blanco Mariano A |
Use of RNA trans-splicing for generation of interfering RNA molecules
|
US7166963B2
(en)
*
|
2004-09-10 |
2007-01-23 |
Axcelis Technologies, Inc. |
Electrodeless lamp for emitting ultraviolet and/or vacuum ultraviolet radiation
|
DE102004047492B4
(de)
*
|
2004-09-23 |
2006-07-20 |
Jost-Werke Gmbh & Co. Kg |
Verfahren zum Übertragen von elektrischer, pneumatischer oder hydraulischer Energie sowie ein Energieübertragungssystem
|
US7871795B2
(en)
|
2004-10-08 |
2011-01-18 |
Virxsys Corporation |
Targeted trans-splicing of highly abundant transcripts for in vivo production of recombinant proteins
|
AU2005326784B2
(en)
*
|
2004-10-08 |
2012-03-15 |
Virxsys Corporation |
Use of RNA trans-splicing for antibody gene transfer and antibody polypeptide production
|
EP2097095B1
(en)
|
2006-11-29 |
2016-01-27 |
Nationwide Children's Hospital |
Myostatin inhibition for enhancing muscle and/or improving muscle function
|
US9415121B2
(en)
|
2008-12-19 |
2016-08-16 |
Nationwide Children's Hospital |
Delivery of MECP2 polynucleotide using recombinant AAV9
|
US11219696B2
(en)
|
2008-12-19 |
2022-01-11 |
Nationwide Children's Hospital |
Delivery of polynucleotides using recombinant AAV9
|
WO2010109053A1
(es)
|
2009-03-27 |
2010-09-30 |
Proyeto De Biomedicina Cima, S.L. |
Métodos y composiciones para el tratamiento de cirrosis y fibrosis hepática
|
SI2424991T1
(sl)
|
2009-05-02 |
2018-11-30 |
Genzyme Corporation |
Genska terapija za nevrodegenerativne motnje
|
CA2780671A1
(en)
|
2009-11-05 |
2011-05-12 |
Proyecto De Biomedicina Cima, S.L. |
Regulated expression system
|
CA2816883A1
(en)
|
2010-11-23 |
2012-05-31 |
Presage Biosciences, Inc. |
Therapeutic methods and compositions for solid delivery
|
US20140155469A1
(en)
|
2011-04-19 |
2014-06-05 |
The Research Foundation Of State University Of New York |
Adeno-associated-virus rep sequences, vectors and viruses
|
US10196636B2
(en)
|
2011-04-21 |
2019-02-05 |
Nationwide Children's Hospital, Inc. |
Recombinant virus products and methods for inhibition of expression of myotilin
|
WO2012145597A2
(en)
|
2011-04-21 |
2012-10-26 |
Nationwide Children's Hospital, Inc. |
Recombinant virus products and methods for inhibition of expression of myotilin
|
US20130039888A1
(en)
|
2011-06-08 |
2013-02-14 |
Nationwide Children's Hospital Inc. |
Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
|
CA3106285A1
(en)
|
2011-07-25 |
2013-01-31 |
Nationwide Children's Hospital, Inc. |
Recombinant virus products and methods for inhibition of expression of dux4
|
US9434928B2
(en)
|
2011-11-23 |
2016-09-06 |
Nationwide Children's Hospital, Inc. |
Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
|
US9163259B2
(en)
|
2012-05-04 |
2015-10-20 |
Novartis Ag |
Viral vectors for the treatment of retinal dystrophy
|
BR112015002168A2
(pt)
|
2012-08-01 |
2017-11-07 |
Nationwide Childrens Hospital |
liberação intratecal de vírus 9 adeno-associado recombinante
|
CA2885216A1
(en)
|
2012-09-17 |
2014-03-20 |
The Research Institute At Nationwide Children's Hospital |
Compositions and methods for treating amyotrophic lateral sclerosis
|
EP2981612B1
(en)
|
2013-04-04 |
2019-07-03 |
Trustees of Dartmouth College |
Compositions and methods for in vivo excision of hiv-1 proviral dna
|
CA2909085C
(en)
|
2013-04-08 |
2023-08-29 |
University Of Iowa Research Foundation |
Chimeric adeno-associated virus/ bocavirus parvovirus vector
|
KR102413498B1
(ko)
|
2013-04-20 |
2022-06-24 |
더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 |
엑손 2-표적 U7snRNA 폴리뉴클레오티드 작제물의 재조합형 아데노 부속 바이러스 전달
|
CN105377039A
(zh)
|
2013-05-15 |
2016-03-02 |
明尼苏达大学董事会 |
腺相关病毒介导的基因向中枢神经系统转移
|
EP4219727A3
(en)
|
2013-08-27 |
2023-09-06 |
Research Institute at Nationwide Children's Hospital |
Products and methods for treatment of amyotrophic lateral sclerosis
|
EP3065784A4
(en)
|
2013-11-05 |
2017-05-10 |
The Research Institute at Nationwide Children's Hospital |
COMPOSITIONS AND METHODS FOR INHIBITING NF- kB AND SOD-1 TO TREAT AMYOTROPHIC LATERAL SCLEROSIS
|
WO2015142984A1
(en)
|
2014-03-18 |
2015-09-24 |
Washington University |
Methods and compositions for red-shifted chromophore substitution for optogenetic applications
|
WO2016025339A2
(en)
|
2014-08-09 |
2016-02-18 |
Research Institute At Nationwide Children's Hospital |
Methods and materials for activating an internal ribosome entry site in exon 5 of the dmd gene
|
US10842886B2
(en)
|
2014-10-10 |
2020-11-24 |
Research Institute At Nationwide Children's Hospital |
Guided injections for AAV gene transfer to muscle
|
CA2966884A1
(en)
|
2014-11-05 |
2016-05-12 |
Research Institute At Nationwide Children's Hospital |
Methods and materials for producing recombinant viruses in eukaryotic microalgae
|
CA2975447C
(en)
|
2015-01-30 |
2021-02-23 |
The Regents Of The University Of California |
Spinal subpial gene delivery system
|
MA41451A
(fr)
|
2015-02-04 |
2017-12-12 |
Univ Washington |
Constructions anti-tau
|
WO2016135558A2
(en)
|
2015-02-23 |
2016-09-01 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
US20180289839A1
(en)
|
2015-05-15 |
2018-10-11 |
Regents Of The University Of Minnesota |
Intranasal therapeutic delivery of adeno-associated virus to central nervous system
|
US10017832B2
(en)
|
2015-08-25 |
2018-07-10 |
Washington University |
Compositions and methods for site specific recombination at asymmetric sites
|
CN108136049A
(zh)
|
2015-09-17 |
2018-06-08 |
全国儿童医院研究所 |
Galgt2基因治疗的方法和材料
|
US20190048340A1
(en)
|
2015-09-24 |
2019-02-14 |
Crispr Therapeutics Ag |
Novel family of rna-programmable endonucleases and their uses in genome editing and other applications
|
US11369692B2
(en)
|
2015-10-28 |
2022-06-28 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of Duchenne Muscular Dystrophy
|
EP3371305A1
(en)
|
2015-11-06 |
2018-09-12 |
Crispr Therapeutics AG |
Materials and methods for treatment of glycogen storage disease type 1a
|
MX2018006116A
(es)
|
2015-11-16 |
2019-04-04 |
Res Institute At Nationwide Children´S Hospital |
Materiales y metodos para el tratamiento de miopatias basadas en titina y otras titinopatias.
|
JP6932698B2
(ja)
|
2015-12-01 |
2021-09-08 |
クリスパー・セラピューティクス・アクチェンゲゼルシャフトCRISPR Therapeutics AG |
アルファ1アンチトリプシン欠乏症の治療のための材料および方法
|
KR20180118111A
(ko)
|
2015-12-23 |
2018-10-30 |
크리스퍼 테라퓨틱스 아게 |
근위축성 측색 경화증 및/또는 전두측두엽 퇴행의 치료 물질 및 방법
|
WO2017120589A1
(en)
|
2016-01-08 |
2017-07-13 |
Washington University |
Compositions comprising chemerin and methods of use thereof
|
US20190038771A1
(en)
|
2016-02-02 |
2019-02-07 |
Crispr Therapeutics Ag |
Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
|
WO2017139381A1
(en)
|
2016-02-08 |
2017-08-17 |
University Of Iowa Research Foundation |
Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
|
US20190112353A1
(en)
|
2016-02-18 |
2019-04-18 |
Crispr Therapeutics Ag |
Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
|
US11066456B2
(en)
|
2016-02-25 |
2021-07-20 |
Washington University |
Compositions comprising TREM2 and methods of use thereof
|
JP6966463B2
(ja)
|
2016-02-26 |
2021-11-17 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
組換えウイルス産物及びdux4エクソンスキッピングを誘導するための方法
|
WO2017158422A1
(en)
|
2016-03-16 |
2017-09-21 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hereditary haemochromatosis
|
CA3018960C
(en)
|
2016-03-28 |
2023-09-26 |
The Regents Of The University Of California |
Method and composition for treating neuronal hyper-excitability
|
IL262056B2
(en)
|
2016-04-02 |
2023-10-01 |
Res Inst Nationwide Childrens Hospital |
The U6 precursor system is optimized for tissue-specific expression
|
MA45477A
(fr)
|
2016-04-15 |
2019-02-20 |
Res Inst Nationwide Childrens Hospital |
Administration à vecteurs de virus adéno-associé de microarn-29 et micro-dystrophine pour traiter la dystrophie musculaire
|
CN109121395B
(zh)
|
2016-04-15 |
2022-08-09 |
全国儿童医院研究所 |
腺相关病毒载体递送β-肌聚糖和微RNA-29以及肌营养不良症的治疗
|
SG11201809144XA
(en)
|
2016-04-18 |
2018-11-29 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
WO2017191503A1
(en)
|
2016-05-05 |
2017-11-09 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
US11427838B2
(en)
|
2016-06-29 |
2022-08-30 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
|
EP3478828B1
(en)
|
2016-06-29 |
2024-09-04 |
CRISPR Therapeutics AG |
Materials and methods for treatment of friedreich ataxia and other related disorders
|
EP3478313B1
(en)
|
2016-06-29 |
2022-05-04 |
CRISPR Therapeutics AG |
Materials and methods for treatment of amyotrophic lateral sclerosis (als) and other related disorders
|
CA3029132A1
(en)
|
2016-07-06 |
2018-01-11 |
Crispr Therapeutics Ag |
Materials and methods for treatment of pain related disorders
|
JP7548696B2
(ja)
|
2016-07-06 |
2024-09-10 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
疼痛関連障害を処置するための物質及び方法
|
WO2018007871A1
(en)
|
2016-07-08 |
2018-01-11 |
Crispr Therapeutics Ag |
Materials and methods for treatment of transthyretin amyloidosis
|
WO2018020323A2
(en)
|
2016-07-25 |
2018-02-01 |
Crispr Therapeutics Ag |
Materials and methods for treatment of fatty acid disorders
|
JP2020500928A
(ja)
|
2016-11-15 |
2020-01-16 |
リジェネクスバイオ インコーポレイテッド |
Mpsiおよびmpsiiならびに他の神経障害において神経機能を改善するための方法
|
MA46863A
(fr)
|
2016-11-17 |
2019-09-25 |
Kevin Foust |
Administration intrathécale de virus adéno-associé recombinant codant pour la protéine 2 de liaison méthyl-cpg
|
RU2019119272A
(ru)
|
2016-11-23 |
2020-12-24 |
Гритстоун Онколоджи, Инк. |
Вирусная доставка неоантигенов
|
CN110191955B
(zh)
|
2016-12-13 |
2024-05-31 |
西雅图儿童医院(Dba西雅图儿童研究所) |
在体外和体内对工程化的细胞中表达的化学物质诱导的信号传导复合物进行外源性药物激活的方法
|
US11142775B2
(en)
|
2017-01-13 |
2021-10-12 |
University Of Iowa Research Foundation |
Bocaparvovirus small noncoding RNA and uses thereof
|
US11781116B2
(en)
|
2017-02-17 |
2023-10-10 |
Lonza Ltd. |
Mammalian cells for producing adeno-associated viruses
|
WO2018154418A1
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
|
EP3585898A1
(en)
|
2017-02-22 |
2020-01-01 |
CRISPR Therapeutics AG |
Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders
|
US11407997B2
(en)
|
2017-02-22 |
2022-08-09 |
Crispr Therapeutics Ag |
Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanine-glyoxylate aminotransferase (AGXT) gene related conditions or disorders
|
WO2018154462A2
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
|
JP2020508056A
(ja)
|
2017-02-22 |
2020-03-19 |
クリスパー・セラピューティクス・アクチェンゲゼルシャフトCRISPR Therapeutics AG |
遺伝子編集のための組成物および方法
|
JP7162021B2
(ja)
|
2017-03-17 |
2022-10-27 |
ニューカッスル ユニバーシティ |
筋ジストロフィーを治療するためのマイクロジストロフィン断片のアデノ随伴ウイルスベクター送達
|
HUE062476T2
(hu)
|
2017-03-17 |
2023-11-28 |
Res Inst Nationwide Childrens Hospital |
Izomspecifikus mikrodisztrofin adenoasszociáltvírus-vektor által történõ bejuttatása izomdisztrófia kezelésére
|
CA3062591A1
(en)
|
2017-05-08 |
2018-11-15 |
Gritstone Oncology, Inc. |
Alphavirus neoantigen vectors
|
IL270415B2
(en)
|
2017-05-12 |
2024-08-01 |
Crispr Therapeutics Ag |
Materials and methods for cell engineering and their uses in immuno-oncology
|
CA3068906A1
(en)
|
2017-07-08 |
2019-01-17 |
Genethon |
Treatment of spinal muscular atrophy
|
CN110892064A
(zh)
|
2017-07-25 |
2020-03-17 |
牛津遗传学有限公司 |
腺病毒载体
|
SG11202003464VA
(en)
|
2017-10-17 |
2020-05-28 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing for hemophilia a
|
EP3697915A4
(en)
|
2017-10-18 |
2021-12-08 |
Research Institute at Nationwide Children's Hospital |
ADENO-ASSOCIATED VIRUS VECTOR ADMINISTRATION OF MUSCLE SPECIFIC MICRODYSTROPHIN FOR THE TREATMENT OF MUSCLE DYSTROPHY
|
WO2019079755A1
(en)
|
2017-10-20 |
2019-04-25 |
Research Institute At Nationwide Children's Hospital |
METHODS AND MATERIALS FOR NT-3 GENE THERAPY
|
EP3701029A1
(en)
|
2017-10-26 |
2020-09-02 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of hemoglobinopathies
|
JP2021502123A
(ja)
|
2017-11-08 |
2021-01-28 |
アヴェクシス インコーポレーテッド |
ウイルスベクターの調製手段及び方法並びにその使用
|
US20210363521A1
(en)
|
2017-11-09 |
2021-11-25 |
Vertex Pharmaceuticals Incorporated |
CRISPR/CAS Systems For Treatment of DMD
|
WO2019102381A1
(en)
|
2017-11-21 |
2019-05-31 |
Casebia Therapeutics Llp |
Materials and methods for treatment of autosomal dominant retinitis pigmentosa
|
US11578323B2
(en)
|
2017-12-14 |
2023-02-14 |
Bayer Healthcare Llc |
RNA-programmable endonuclease systems and their use in genome editing and other applications
|
WO2019123430A1
(en)
|
2017-12-21 |
2019-06-27 |
Casebia Therapeutics Llp |
Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp)
|
WO2019123429A1
(en)
|
2017-12-21 |
2019-06-27 |
Casebia Therapeutics Llp |
Materials and methods for treatment of usher syndrome type 2a
|
EP3735271A4
(en)
|
2018-01-04 |
2022-06-15 |
Iconic Therapeutics, Inc. |
ANTI-TISSUE FACTOR ANTIBODIES, ANTIBODY DRUG CONJUGATES AND RELATED METHODS
|
EP3737762A1
(en)
|
2018-01-12 |
2020-11-18 |
CRISPR Therapeutics AG |
Compositions and methods for gene editing by targeting transferrin
|
US11566236B2
(en)
|
2018-02-05 |
2023-01-31 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of hemoglobinopathies
|
MA51788A
(fr)
|
2018-02-05 |
2020-12-16 |
Vertex Pharma |
Substances et méthodes pour traiter des hémoglobinopathies
|
US20210130824A1
(en)
|
2018-02-16 |
2021-05-06 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing by targeting fibrinogen-alpha
|
JP7550648B2
(ja)
|
2018-03-19 |
2024-09-13 |
クリスパー セラピューティクス アーゲー |
新規rnaプログラム可能エンドヌクレアーゼ系およびその使用
|
WO2019204668A1
(en)
|
2018-04-18 |
2019-10-24 |
Casebia Therapeutics Limited Liability Partnership |
Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease
|
WO2019210057A1
(en)
|
2018-04-27 |
2019-10-31 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Rapamycin resistant cells
|
CN112601557A
(zh)
|
2018-06-08 |
2021-04-02 |
诺华股份有限公司 |
用于测量药物产品效力的基于细胞的测定
|
GB201809588D0
(en)
|
2018-06-12 |
2018-07-25 |
Univ Bristol |
Materials and methods for modulating intraocular and intracranial pressure
|
CA3104471A1
(en)
|
2018-06-18 |
2019-12-26 |
Research Institute At Nationwide Children's Hospital |
Recombinant adeno-associated virus products and methods for treating dystroglycanopathies and laminin-deficient muscular dystrophies
|
JP2021527657A
(ja)
|
2018-06-18 |
2021-10-14 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
筋ジストロフィーを治療するための筋肉特異的マイクロジストロフィンのアデノ随伴ウイルスベクターデリバリー
|
KR20210028162A
(ko)
|
2018-06-29 |
2021-03-11 |
더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 |
지대근 이영양증 2a형을 치료하기 위한 재조합 아데노 연관 바이러스 생성물 및 방법
|
AU2019328270A1
(en)
|
2018-08-29 |
2021-03-25 |
Research Institute At Nationwide Children's Hospital |
Products and methods for inhibition of expression of mutant GARS protein
|
JP7320601B2
(ja)
|
2018-09-11 |
2023-08-03 |
上▲海▼市公共▲衛▼生▲臨▼床中心 |
広域スペクトルな抗インフルエンザワクチン免疫原及びその使用
|
AU2019362000A1
(en)
|
2018-10-17 |
2021-05-20 |
Bayer Healthcare Llc |
Compositions and methods for delivering transgenes
|
MX2021006359A
(es)
|
2018-11-30 |
2021-08-11 |
Novartis Ag |
Vectores virales de vaa y sus usos.
|
US20220042045A1
(en)
|
2018-12-21 |
2022-02-10 |
Genethon |
Expression cassettes for gene therapy vectors
|
US20220106592A1
(en)
|
2018-12-31 |
2022-04-07 |
Research Institute At Nationwide Children's Hospital |
DUX4 RNA Silencing Using RNA Targeting CRISPR-CAS13b
|
KR20210124300A
(ko)
|
2019-02-04 |
2021-10-14 |
더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 |
Cln3 폴리뉴클레오티드의 아데노-관련 바이러스 전달
|
KR20210124299A
(ko)
|
2019-02-04 |
2021-10-14 |
더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 |
Cln6 폴리뉴클레오티드의 아데노-관련 바이러스 전달
|
US11529427B2
(en)
|
2019-02-15 |
2022-12-20 |
Crispr Therapeutics Ag |
Gene editing for hemophilia A with improved factor VIII expression
|
JP2022520875A
(ja)
|
2019-02-25 |
2022-04-01 |
ノバルティス アーゲー |
Biettiクリスタリン網膜症を治療するための組成物及び方法
|
CN113677801A
(zh)
|
2019-02-25 |
2021-11-19 |
诺华股份有限公司 |
治疗bietti晶体营养不良的组合物和方法
|
MX2021010356A
(es)
|
2019-02-26 |
2022-03-04 |
Res Inst Nationwide Childrens Hospital |
SUMINISTRO DE ß-SARCOGLICANO MEDIANTE VECTORES DE VIRUS ADENOASOCIADO Y EL TRATAMIENTO DE LA DISTROFIA MUSCULAR.
|
EP3937963A2
(en)
|
2019-03-12 |
2022-01-19 |
CRISPR Therapeutics AG |
Novel high fidelity rna-programmable endonuclease systems and uses thereof
|
JP2022529457A
(ja)
|
2019-04-15 |
2022-06-22 |
ユニヴァーシティ オブ アイオワ リサーチ ファウンデーション |
嚢胞性線維症の治療のための組成物及び方法
|
US20220195461A1
(en)
|
2019-04-15 |
2022-06-23 |
University Of Iowa Research Foundation |
Methods and compositions for transgene expression
|
US20220193259A1
(en)
|
2019-04-15 |
2022-06-23 |
Sanford Research |
Gene therapy for treating or preventing visual effects in batten disease
|
EP3966327A1
(en)
|
2019-05-08 |
2022-03-16 |
Vertex Pharmaceuticals Incorporated |
Crispr/cas all-in-two vector systems for treatment of dmd
|
EP3969060A1
(en)
|
2019-05-17 |
2022-03-23 |
Research Institute at Nationwide Children's Hospital |
Optimized gene therapy targeting retinal cells
|
JP7457733B2
(ja)
|
2019-05-30 |
2024-03-28 |
グリットストーン バイオ インコーポレイテッド |
改変アデノウイルス
|
MA56393A
(fr)
|
2019-06-28 |
2022-05-04 |
Bayer Healthcare Llc |
Matériels et méthodes de régulation de l'édition de gènes
|
JP2022541070A
(ja)
|
2019-07-25 |
2022-09-21 |
ノバルティス アーゲー |
調節可能な発現系
|
ES2978666T3
(es)
|
2019-08-21 |
2024-09-17 |
Res Institute At Nationwidechildrens Hospital |
Suministro de alfa-sarcoglicano por vector de virus adenoasociado y tratamiento de la distrofia muscular
|
WO2021072115A1
(en)
|
2019-10-08 |
2021-04-15 |
Regents Of The University Of Minnesota |
Crispr-mediated human genome editing with vectors
|
AU2020366531A1
(en)
|
2019-10-18 |
2022-05-26 |
Research Institute At Nationwide Children's Hospital |
Gene therapy targeting cochlear cells
|
WO2021077101A1
(en)
|
2019-10-18 |
2021-04-22 |
Research Institute At Nationwide Children's Hospital |
Materials and methods for the treatment of disorders associated mutations in the irf2bpl gene
|
US20230211018A1
(en)
|
2019-11-22 |
2023-07-06 |
Research Institute At Nationwide Children's Hospital |
Materials and methods for treatment of disorders associated with the ighmbp2 gene
|
CA3165469A1
(en)
|
2019-12-20 |
2021-06-24 |
Research Institute At Nationwide Children's Hospital |
Optimized gene therapy for targeting muscle in muscle diseases
|
CA3171959A1
(en)
|
2020-02-18 |
2021-08-26 |
Research Institute At Nationwide Children's Hospital |
Aav-mediated targeting of mirna in the treatment of x-linked disorders
|
CA3174863A1
(en)
|
2020-04-14 |
2021-10-21 |
Ana BUJ BELLO |
Vectors for the treatment of acid ceramidase deficiency
|
WO2021257595A1
(en)
|
2020-06-15 |
2021-12-23 |
Research Institute At Nationwide Children's Hospital |
Adeno-associated virus vector delivery for muscular dystrophies
|
US20230242941A1
(en)
|
2020-06-30 |
2023-08-03 |
Eric Yuen |
Methods and compositions for administering recombinant viral vectors
|
US20230374483A1
(en)
|
2020-07-08 |
2023-11-23 |
Regents Of The University Of Minnesota |
Modified hexosaminidase and uses thereof
|
WO2022018638A1
(en)
|
2020-07-21 |
2022-01-27 |
Crispr Therapeutics Ag |
Genome-editing compositions and methods to modulate faah for treatment of neurological disorders
|
KR20230054840A
(ko)
|
2020-07-30 |
2023-04-25 |
셰이프 테라퓨틱스 인코포레이티드 |
rAAV 비리온의 유도 생산을 위한 안정화된 세포주
|
WO2022032196A2
(en)
|
2020-08-06 |
2022-02-10 |
Gritstone Bio, Inc. |
Multiepitope vaccine cassettes
|
US20230414787A1
(en)
|
2020-08-27 |
2023-12-28 |
University Of Iowa Research Foundation |
Gene knock-out for treatment of glaucoma
|
TW202227634A
(zh)
|
2020-09-08 |
2022-07-16 |
美商薩羅塔治療公司 |
表現γ—肌聚醣之腺相關病毒載體之全身性遞送及肌肉失養症之治療
|
US20230357795A1
(en)
|
2020-09-15 |
2023-11-09 |
Research Institute At Nationwide Children's Hospital |
Aav-mediated homology-independent targeted integration gene editing for correction of diverse dmd mutations in patients with muscular dystrophy
|
AU2021349277A1
(en)
|
2020-09-28 |
2023-05-11 |
Research Institute At Nationwide Children's Hospital |
Products and methods for treating muscular dystrophy
|
US20230392134A1
(en)
|
2020-09-30 |
2023-12-07 |
Crispr Therapeutics Ag |
Materials and methods for treatment of amyotrophic lateral sclerosis
|
JP2023551279A
(ja)
|
2020-11-30 |
2023-12-07 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
顔面肩甲上腕筋ジストロフィー(fshd)を治療するための組成物及び方法
|
US20220228142A1
(en)
|
2020-12-17 |
2022-07-21 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for editing beta-globin for treatment of hemaglobinopathies
|
CA3209471A1
(en)
|
2021-01-27 |
2022-08-04 |
Research Institute At Nationwide Children's Hospital |
Materials and methods for the treatment of lysosomal acid lipase deficiency (lal-d)
|
WO2022169922A1
(en)
|
2021-02-03 |
2022-08-11 |
Research Institute At Nationwide Children's Hospital |
Compositions and methods for treating disease associated with dux4 overexpression
|
WO2022170038A1
(en)
|
2021-02-05 |
2022-08-11 |
Amicus Therapeutics, Inc. |
Adeno-associated virus delivery of cln3 polynucleotide
|
WO2022170082A1
(en)
|
2021-02-05 |
2022-08-11 |
Regents Of The University Of Minnesota |
Methods for preventing cardiac or skeletal defects in diseases including mucopolysaccharidoses
|
US20240254509A1
(en)
|
2021-03-04 |
2024-08-01 |
Research Institute At Nationwide Children's Hospital |
Products and methods for treatment of dystrophin-based myopathies using crispr-cas9 to correct dmd exon duplications
|
WO2022188797A1
(en)
|
2021-03-09 |
2022-09-15 |
Huigene Therapeutics Co., Ltd. |
Engineered crispr/cas13 system and uses thereof
|
CA3216711A1
(en)
|
2021-04-13 |
2022-10-20 |
Research Institute At Nationwide Children's Hospital |
Recombinant adeno-associated virus encoding methyl-cpg binding protein 2 for treating pitt hopkins syndrome via intrathecal delivery
|
EP4323011A1
(en)
|
2021-04-15 |
2024-02-21 |
Spirovant Sciences, Inc. |
Methods and compositions for treatment of cystic fibrosis
|
JP2024515720A
(ja)
|
2021-04-23 |
2024-04-10 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
筋ジストロフィーを治療するための製品及び方法
|
WO2022234295A1
(en)
|
2021-05-07 |
2022-11-10 |
Ucl Business Ltd |
Abca4 genome editing
|
MX2023013561A
(es)
|
2021-05-17 |
2024-02-12 |
Sarepta Therapeutics Inc |
Produccion de vectores de aav recombinantes para tratamiento de distrofia muscular.
|
EP4108263A3
(en)
|
2021-06-02 |
2023-03-22 |
Research Institute at Nationwide Children's Hospital |
Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2a
|
EP4101928A1
(en)
|
2021-06-11 |
2022-12-14 |
Bayer AG |
Type v rna programmable endonuclease systems
|
BR112023023768A2
(pt)
|
2021-06-11 |
2024-02-27 |
Bayer Ag |
Sistemas de endonucleases programáveis por rna tipo v
|
WO2023283962A1
(en)
|
2021-07-16 |
2023-01-19 |
Huigene Therapeutics Co., Ltd. |
Modified aav capsid for gene therapy and methods thereof
|
CN118159656A
(zh)
|
2021-08-11 |
2024-06-07 |
坚固生物科技公司 |
肌营养不良的治疗
|
EP4144841A1
(en)
|
2021-09-07 |
2023-03-08 |
Bayer AG |
Novel small rna programmable endonuclease systems with impoved pam specificity and uses thereof
|
EP4402265A1
(en)
|
2021-09-16 |
2024-07-24 |
Novartis AG |
Novel transcription factors
|
WO2023060215A1
(en)
|
2021-10-07 |
2023-04-13 |
Research Institute At Nationwide Children's Hospital |
Products and methods for myelin protein zero silencing and treating cmt1b disease
|
EP4413376A1
(en)
|
2021-10-08 |
2024-08-14 |
Amicus Therapeutics, Inc. |
Biomarkers for lysosomal storage diseases
|
JP2023059858A
(ja)
|
2021-10-15 |
2023-04-27 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
自己相補的アデノ随伴ウイルスベクター及び筋ジストロフィーの治療におけるその使用
|
JP2023081369A
(ja)
|
2021-11-30 |
2023-06-09 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
自己相補的アデノ随伴ウイルスベクター及び筋ジストロフィーの治療におけるその使用
|
EP4198048A1
(en)
|
2021-12-16 |
2023-06-21 |
Genethon |
Calpain-3 gene transfer increase using modified itr sequences
|
EP4198046A1
(en)
|
2021-12-16 |
2023-06-21 |
Genethon |
Alpha-sarcoglycan gene transfer increase using modified itr sequences
|
EP4198134A1
(en)
|
2021-12-16 |
2023-06-21 |
Genethon |
Gamma-sarcoglycan gene transfer increase using modified itr sequences
|
EP4198047A1
(en)
|
2021-12-16 |
2023-06-21 |
Genethon |
Fukutin related protein gene transfer increase using modified itr sequences
|
WO2023122669A1
(en)
|
2021-12-21 |
2023-06-29 |
Research Institute At Nationwide Children's Hospital |
Materials and methods for the treatment of limb girdle muscular dystrophy
|
WO2023118068A1
(en)
|
2021-12-23 |
2023-06-29 |
Bayer Aktiengesellschaft |
Novel small type v rna programmable endonuclease systems
|
WO2023166425A1
(en)
|
2022-03-01 |
2023-09-07 |
Crispr Therapeutics Ag |
Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
|
WO2023168400A2
(en)
|
2022-03-03 |
2023-09-07 |
Research Institute At Nationwide Children's Hospital |
Materials and methods for the treatment of eif2b5 mutations and diseases resulting therefrom
|
WO2023196818A1
(en)
|
2022-04-04 |
2023-10-12 |
The Regents Of The University Of California |
Genetic complementation compositions and methods
|
TW202404993A
(zh)
|
2022-04-11 |
2024-02-01 |
美商特納亞治療股份有限公司 |
具經工程化蛋白殼之腺相關病毒
|
WO2023214346A1
(en)
|
2022-05-06 |
2023-11-09 |
Novartis Ag |
Novel recombinant aav vp2 fusion polypeptides
|
WO2023240177A1
(en)
|
2022-06-08 |
2023-12-14 |
Research Instiitute At Nationwide Children's Hospital |
Products and methods for treating diseases or conditions associated with mutant or pathogenic kcnq3 expression
|
WO2023237587A1
(en)
|
2022-06-10 |
2023-12-14 |
Bayer Aktiengesellschaft |
Novel small type v rna programmable endonuclease systems
|
WO2024011115A1
(en)
|
2022-07-06 |
2024-01-11 |
Research Institute At Nationwide Children's Hospital |
Adeno-associated virus delivery of cln1 polynucleotide
|
WO2024035782A1
(en)
|
2022-08-10 |
2024-02-15 |
Aav Gene Therapeutics, Inc. |
Aav-mediated intramuscular delivery of insulin
|
WO2024064913A1
(en)
|
2022-09-23 |
2024-03-28 |
Sarepta Therapeutics, Inc. |
Recombinant aav vectors for treating muscular dystrophy
|
WO2024081706A1
(en)
|
2022-10-11 |
2024-04-18 |
Research Institute At Nationwide Children's Hospital |
Adeno-associated virus delivery to treat spinal muscular atrophy with respiratory distress type 1 (smard1) and charcot-marie-tooth type 2s (cmt2s)
|
WO2024086747A1
(en)
|
2022-10-19 |
2024-04-25 |
Affinia Therapeutics Inc. |
Recombinant aavs with improved tropism and specificity
|
WO2024092171A1
(en)
|
2022-10-26 |
2024-05-02 |
University Of Iowa Research Foundation |
Method to deliver large genes using virus and a dna recombination system
|
WO2024092126A1
(en)
|
2022-10-27 |
2024-05-02 |
Cargo Therapeutics, Inc. |
Compositions and methods for improved immunotherapies
|
WO2024129743A2
(en)
|
2022-12-13 |
2024-06-20 |
Bluerock Therapeutics Lp |
Engineered type v rna programmable endonucleases and their uses
|
WO2024151982A1
(en)
|
2023-01-13 |
2024-07-18 |
Amicus Therapeutics, Inc. |
Gene therapy constructs for the treatment of pompe disease
|
WO2024163560A1
(en)
|
2023-02-01 |
2024-08-08 |
Sarepta Therapeutics, Inc. |
Raav production methods
|
WO2024168276A2
(en)
|
2023-02-09 |
2024-08-15 |
Cargo Therapeutics, Inc. |
Compositions and methods for immunotherapies
|